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Abstract 
Background: This study aims to explore how patients with metastatic gastrointestinal stromal tumour (GIST) experi-
ence the adverse effects of treatment, as expressed by the individuals themselves.
Methods: A qualitative, phenomenological and hermeneutic design was applied. Twenty patients with metastatic 
GIST participated in the study. In-depth and semi-structured interviews were conducted and then analysed by means 
of an inductive thematic analysis.
Results: The majority of participants reported experiencing a changed life after being diagnosed with metastatic 
GIST and commencing systemic medical treatment. More than half of them described partially debilitating self-
reported side effects and complaints that had a detrimental impact on their lives. The life-prolonging tyrosine kinase 
inhibitor treatment prompted the participants to adapt to ‘a new normal’. Several participants also emphasised having 
an ambivalent relationship with the pill, although most looked upon it as ‘a friend’ because it kept them alive. Para-
doxically, while the participants struggled with the side effects of treatment as well as the consequences of living with 
a chronic cancer, half of them considered themselves to be healthy and, thus, to not actually be cancer patients.
Conclusions: We observed a gap between the biomedical perspective on disease that health professionals typically 
adopt and the individual experiences of patients living with metastatic GIST. For those patients who are living in limbo 
between having metastatic cancer and offered an effective treatment, a holistic view of health on the part of their 
healthcare providers seems crucial. A vital goal should hence be to improve communication between healthcare pro-
fessionals and GIST patients so as to secure an individualised follow-up with guidance on coping with, and adapting 
to, their new normal.
Trial registration The study was approved by the data protection officer of the Oslo University Hospital (Approval Num-
ber 2016/15358)
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Background
Recent progress in the field of medical oncology has 
increasingly rendered cancer a chronic disease, with 
metastatic gastrointestinal stromal tumours (GIST) 
being a prime example of this phenomenon. Due to the 
seminal discovery of KIT mutations in cases of GIST [1], 
alongside the subsequent introduction of the tyrosine 
kinase inhibitor (TKI) imatinib [2, 3], metastatic GIST 
has changed from being a highly aggressive type of can-
cer that caused the death of almost all patients within the 
first year of diagnosis [4] to being a chronic cancer with 
a median overall survival rate of approximately 7  years 
[5]. Indeed, imatinib and the other TKIs that have been 
introduced as effective treatments for metastatic GISTs 
induce long-term remission in the majority of patients 
and, for some, even result in an extended life expec-
tancy of decades [5, 6]. However, although imatinib has 
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revolutionised the treatment of metastatic GIST, most 
patients will eventually experience drug resistance [3]. 
This is particularly true in cases of treatment with sec-
ond- [7] and third-line TKIs.
Imatinib is taken orally on a daily basis, and it is con-
sidered to be moderately to well tolerated, at least 
when compared to conventional chemotherapy [8]. 
Although severe adverse effects are uncommon, virtu-
ally all patients treated with imatinib report some side 
effects, with the most frequent being anaemia, periorbital 
oedema and watery eyes, diarrhoea, muscle cramps (typi-
cally in the hands and legs), fatigue and nausea [3, 9].
In addition to the well-known medical side effects of 
imatinib, several practical and psychosocial challenges 
may influence the daily lives of patients, although the 
extent to which this is the case has not yet been well 
studied. For instance, as most patients with metastatic 
GIST eventually will succumb to their disease [6, 10], the 
fear of disease progression is undeniably a challenge for 
patients and their families [11].
Further, in one study, the prevalence of severe fatigue 
among 61 GIST patients who were receiving TKI treat-
ment was found to be significantly higher (30%) when 
compared to the matched healthy controls (15%) [12]. 
The fatigued patients reported a lower quality of life 
(QoL) as well as increased impairment in all the func-
tional domains, including psychological distress and 
physical functioning. Another study described the 
extended lifetime that results from the TKI treatment 
of GIST as being akin to a Sword of Damocles [11]. The 
patients reported a good global QoL, although the major-
ity also reported a considerable fear of disease progres-
sion. They experienced significantly higher levels of 
psychological distress, functional impairments and diffi-
culty making plans for the future [11].
Being ill as a result of a serious disease not only affects a 
part of an individual’s body or an organ, but also impacts 
his/her practical, social, intellectual and emotional needs. 
To the best of our knowledge, only one study concerning 
GIST that had a qualitative design (mixed methods) has 
previously been conducted [13]. That study emphasised 
that patients with metastatic GIST shared similar emo-
tional journeys. The patients were found to experience 
five stages of disease management, namely crisis, hope, 
adaptation, ‘new normal’ and uncertainty. This entire 
process was found to have a detrimental impact on their 
lives [13].
In the current study, our aim was to explore how 
patients with metastatic GIST experience both living 
with their disease and the adverse effects of its treatment. 
By adopting a qualitative method involving a phenom-
enological approach that utilised an explanatory design, 
we aimed to better understand how patients voice their 
experiences.
Methods
This study adopts a psychosocial and sociocultural per-
spective on health and illness in order to identify the rea-
sons behind the experienced phenomena, as expressed 
by the participants themselves. In line with the study’s 
methodological framework and research questions, we 
have applied a phenomenological experience-based and 
hermeneutics interpretation-based approach to disease 
and illness [14, 15]. Phenomenological research aims to 
investigate individual human experiences (phenomena) 
as they manifest in both daily life and specific situations 
[16], while hermeneutics relates to the methods devel-
oped for achieving an understanding and interpretation 
of phenomena in a comprehensible manner [17]. Here, 
comprehension develops through the entire process, and 
it is based on the participant’s and the researcher’s pre-
understandings, as well as on the historical and cultural 
contexts.
Patients
Patients with metastatic GIST who were treated at the 
Department of Oncology, Norwegian Radium Hospital, 
Oslo University Hospital (NRH OUH), were included 
in this qualitative study. They were identified from the 
prospective sarcoma registry at the NRH OUH and 
their clinical data were extracted from that database. 
The inclusion criteria were: (i) confirmed metastatic 
GIST, (ii) receiving treatment with TKIs for at least 
2  years prior to inclusion in the study and (iii) stable 
disease, which was defined as no change in the admin-
istration of the TKI. The study cohort consisted of 20 
patients, 11 women and nine men, with a median age 
of 61 years (range 36–85). They all did write and speak 
Norwegian and were all undergoing regular follow-up 
at our sarcoma outpatient clinics. In the results sec-
tion, the participants are identified by their gender and 
age. Demographic and clinical information concerning 
the participants is presented in Table  1. Twelve of the 
participants received the conventional 400  mg dose of 
imatinib, four had reduction of the dose to 200 mg due 
to adverse events, whereas two had dose escalation up 
to 800 mg due to disease progression on 400 mg. Two 
participants received sunitinib.
Procedure
The recruitment of participants was performed by the 
treating oncologists at the NRH OUH. The first author 
provided detailed information regarding all the relevant 
aspects of study participation and also conducted the 
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interviews. The average length of the interviews was 
45 min (16 to 82 min). Sixteen interviews were conducted 
in relation to a previously scheduled routine clinical fol-
low-up appointment at the NRH OUH, while four were 
conducted in the participants’ home. The interviews fol-
lowed a semi-structured guide and they were conducted 
on a face-to-face basis. The interviews were transcribed 
verbatim by a medical secretary. The interview guide 
invited the participants to narrate their whole story from 
the time of diagnosis to the present day, and it included 
the following main topics: How do the disease and its 
treatment affect your daily life? How is your relationship 
with the pill? Do you consider yourself to be healthy or 
ill? (Additional file 1). All the collected information was 
stored confidentially, and thematic analyses were con-
ducted on anonymised transcripts.
The study was approved by the data protection officer 
of the NRH OUH (Approval Number 2016/15358), and 
written informed consent was obtained from all partici-
pants prior to beginning the study.
Data analysis
A thematic analysis is a qualitative approach that has 
been widely applied across the social, behavioural and 
applied health sciences [18]. The purpose of this method 
is to identify patterns of meaning across a dataset in 
order to answer the research question being addressed. 
The patterns are identified through a process of data 
familiarisation and data coding, as well as through theme 
development and revision. In this study, the entire data-
set was coded in detail (i.e. a thorough, inclusive and 
extensive coding approach) by hand by the first author, as 
well as partly by the third and fourth authors. The codes 
were then divided into themes and concepts. The emer-
gent themes formed the core of the analysis, and they 
were reflected upon in accordance with the study’s objec-
tives and also compared with the existing literature and 
theory [18]. Throughout the entire process of analysis, 
the researcher regularly returned to the original data to 
check the themes and quotes, as well as to ensure that the 
meaning had not been lost during either interpretation or 
translation [19].
Results
The majority of participants reported experiencing a 
changed life after being diagnosed with a GIST and 
beginning systemic treatment. The crucial life-pro-
longing TKI treatment had side effects that influenced 
their daily lives in negative and challenging ways, which 
caused the participants to adapt to ‘a new normal’. Sev-
eral participants emphasised that they had an ambivalent 
relationship with the pill, although most looked upon 
Table 1 Baseline demographic and  clinical data 
concerning the study cohort
The values given in parentheses are percentages unless otherwise indicated, 
avalues are the median (range)
PDGFRA platelet-derived growth factor α-gene
Total number of patients 20
Age (years)a 61 (36–85)
Sex
 Female 11 (55)
 Male 9 (45)
Relationship status
 Married 9 (45)
 Cohabiting 3 (15)
 Single 8 (40)
Children
 Yes 16 (80)
 No 4 (20)
Time since primary diagnosis (years)a 8 (2–22)
Time receiving systemic treatment (years)a 6 (2–15)
Primary tumour localisation
 Stomach 12 (60)
 Small bowel 7 (35)
 Rectum 1 (5)
KIT/PDGFRA mutations
 KIT exon 11 11 (55)
 KIT exon 9 3 (15)
 KIT exon 13 1 (5)
 PDGFRA exon 18 1 (5)
 PDGFRA exon 12 1 (5)
 Not detected 3 (15)
Metastatic site
 Liver 10 (50)
 Peritoneal 8 (40)
 Liver and peritoneal 2 (10)
Metastasis at diagnosis
 Yes 10 (50)
 No 10 (50)
Previous adjuvant imatinib treatment (12–36 months)
 Yes 5 (25)
 No 15 (75)
Systemic treatment in a metastatic setting
 Imatinib 18 (90)
 Sunitinib 2 (10)
Number of surgeries (including surgery to the primary tumour)
 No surgery 1 (5)
 1 10 (50)
 2 8 (40)
 5 1 (5)
Radiotherapy
 Yes 2 (10)
 No 18 (90)
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it as ‘a friend’ because it kept them alive. Paradoxically, 
while the patients struggled with both the side effects of 
treatment and the consequences of living with a chronic 
cancer, half of them considered themselves to be healthy 
and, thus, to not actually be cancer patients. We identi-
fied two dominant themes, namely self-reported adverse 
treatment effects and the paradoxical self.
Self‑reported adverse treatment effects
The participants reported varying degrees of self-
reported side effects stemming from imatinib and suni-
tinib, although their subjective experiences of those side 
effects and their everyday consequences were similar in 
many ways. In addition to the side effects of taking daily 
medication, several participants pointed out that the 
gastrointestinal surgery had also resulted in challenges, 
such as abdominal pain, dumping syndrome or food 
intolerance.
The majority of participants mentioned the well-known 
side effects of imatinib, such as oedema, especially peri-
orbital oedema, nausea, diarrhoea, muscle cramps, mus-
cle aches, joint pain, tiredness and exhaustion. Many also 
reported experiencing an increased need for sleep, cog-
nitive challenges, reduced sexual desire, as well as poor 
stress tolerance around the intake of the pill. Further-
more, some mentioned alcohol and certain food intoler-
ances, itching, insomnia and neuropathy, among other 
less common side effects (Fig. 1).
Based on their stories, the participants were divided 
into three groups. In the first group were four partici-
pants who had few self-reported side effects and com-
plaints, which had only a minor influence on their 
everyday life, and who lived almost as they did before. In 
the second group were five participants who had some 
self-reported side effects and complaints, which meant 
that they experienced limitations and the need to adjust, 
although their everyday life was reasonably satisfactory. 
In the third group were 11 participants who reported 
extensive, partially debilitating, self-reported side effects 
and complaints that had a detrimental influence on their 
lives.
As mentioned above, more than half of the participants 
reported that the experienced side effects had a consider-
able negative impact on their daily lives. For instance, one 
woman (age 52) experienced the effect of a daily dose of 
400 mg of imatinib as terrible:
‘I had cramps in all the muscles all over my body 
[…] and with a lot of oedema in my face and legs 
[...] I lost two litres of fluid every morning. [...] I also 
got enlarged breasts […] they went up roughly one 
size a year. [...] And I needed a lot of sleep too, I felt 
fatigued.’
She also stated that the medicine reduced her wellbe-
ing, although it did have a positive side: ‘It’s awful that 
there are so many side effects, but then I think it has 
helped me.’ She reduced her dose to 200 mg after a few 
years, which led to fewer side effects and a better life. 
Several others reported that reducing the medication 
dose led to a reduction in complaints. Further, the side 
effects were found to change over time, for example, nau-
sea and cramps might decrease, while tiredness might 
increase. One male participant (47) said:
‘As time has passed, I’ve noticed that I’m a bit 
weaker in my whole body, more tired especially, so 
I go to bed a bit earlier than usual. It seems to be a 
The most common side effects 
from imatinib as subjectively 
expressed by the participants: 
Edema, especially under the eyes, 
nausea, tiredness and being 
exhausted, increased need for 
sleep, cognitive impairment, 
muscle pain and cramps, joint 
pain, decreased sex drive, poor 
stress tolerance during intake of 
the pill. 
Less common adverse effects 
expressed: Diarrhea, alcohol 
intolerance, food intolerance, 
itching, insomnia, neuropathy, 
being more emotional, being less 
happy, running eyes, hot flushes, 
discolored skin, bruises, thin skin, 
light sores, flu sensation, loss of 
creativity, lost eyebrows, 
heartburn, weight gain, strong 
odor of urine and stools, 
headaches, frozen, loss of taste, 
pigment spots, enlarged breasts, 
depressed mood. 
Specific side effects among those 
two on sunitinib were; increased 
fatigue, sore mucous membranes, 
pain during tooth brushing and 
hot drinks  
Fig. 1 Self-reported subjective side effects
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feeling like the one I normally have when getting the 
flu [...], then you feel a bit shivery, in fact it’s a kind of 
normal state. But I think it has come on gradually, I 
don’t think it was like that in the beginning, during 
the first few years.’
Furthermore, several participants stated that their 
tiredness had become more pronounced after they had 
been taking imatinib for some years.
Many participants reported having become used to 
the side effects and having learned to adapt their lives 
accordingly. However, this was not the case for the two 
participants who were on a higher dose (800  mg daily). 
They reported many side effects, several of which were 
exhausting, debilitating and had a profound negative 
effect on their lives. For instance, one woman (49) stated 
that the medicine had such strong side effects that she 
lost all her energy, had a lot of cramps, felt cold and tired 
all the time, and did not dare to meet people, so she just 
stayed indoors. ‘My skin... swollen mucous membranes 
[…] people could hardly recognise me, I developed a 
huge face, you could hardly see my eyes. […] It just devel-
oped and got worse and worse and worse.’ She stressed 
that she had been unprepared for such changes: “I didn’t 
think that this medicine would completely knock me out.’
Sunitinib is the first choice of alternative treatment 
when resistance to imatinib occurs [8]. The two partici-
pants who took sunitinib described more and stronger 
side effects from that drug when compared to what they 
experienced when they took imatinib. Both reported that 
tiredness and exhaustion were more of a challenge than 
before. One male participant (52) described pain in his 
skin and mucous membranes:
‘And physically, I can feel the side effect that I call 
sunburn under the skin. […] I get strong side effects 
if I drink alcohol. I’ve stopped liking coffee, tea and 
hot drinks because my tongue’s very sensitive. […] I 
don’t drink so many fizzy drinks now because getting 
those bubbles on my tongue is like getting barbed 
wire on my tongue. It’s a real drag, the sore feeling in 
my skin and hands, and inside all over my body, and 
in my mouth and mucous membranes, and it hurts 
just to clean my teeth. It really hurts. So, my dental 
hygiene isn’t so good now. Just try to brush your teeth 
with a steel brush. […] And the toothpaste tastes like 
strong whiskey. […] When I use sunitinib, all those 
side effects are very powerful.’
Many participants mentioned the rapid effect of treat-
ment after starting imatinib, with the pain related to the 
disease being reduced after just a few days. They were 
grateful that there was a pill that could reverse the dis-
ease, or at least keep it under control, so that they could 
live with metastatic GIST. However, both the imatinib and 
sunitinib patients stated that there were two sides to the 
coin: ‘It’s both a friend and an enemy - without it I have 
no life. That’s simple maths,’ said a male participant (52). 
He also said that the pill was a daily reminder that he had 
a serious illness, which he otherwise tried not to focus on. 
It extended his life for several more years, but it also led 
to him experiencing many side effects and challenges. The 
majority of participants looked upon the pill as a friend 
because it kept them alive, although they emphasised a 
certain level of ambivalence in relation to it due to all the 
side effects. Despite the latter, none of the participants 
had ever considered stopping taking the drug.
The paradoxical self
Despite having metastatic GISTs, many of the partici-
pants did not think of themselves as being cancer patients 
in their everyday lives. Nevertheless, they emphasised 
how their daily dose of medicine and its side effects reg-
ularly reminded them of their condition. However, they 
continued to feel healthy in their daily lives and, most of 
the time, they hence did not think about their cancer. For 
instance, a young man (36), whose side effects were so 
minimal that he could continue to work, stated:
‘Basically, I consider myself to be healthy, but obvi-
ously I’ve started to understand now, in the last six 
months, or the last year, that I’m still having treat-
ment, so it’s a kind of in-between thing in a way. But 
in my day-to-day life, I’m healthy. [...] As long as I 
can do the things I like doing, I’m content.’
Being healthy was often not voiced as being related 
to a lack of illness, but rather to doing things that were 
important to the participants. One man (73) said, ‘I con-
sider myself to be healthy. I really do. Because I want to 
do things, I like being outdoors, in the woods, picking 
berries and so on, that’s what I’ve done all my life.’ Being 
healthy was related to being able to live a normal life. The 
participants wanted to make the best of their lives and 
to not focus on cancer. One woman (74) said, ‘I’m basi-
cally healthy. So, I try to live as normally as I possibly can.’ 
Even some of those participants who did view themselves 
as cancer patients did not generally talk about their dis-
ease. One woman (51) who experienced many side effects 
of imatinib said:
‘That’s life. […] But the most important thing is to 
make an effort and to try to live as normally as pos-
sible in spite of … [cancer]. […] Having a job, that’s 
really important. Don’t just sit at home thinking 
and brooding, but do everything you used to do. […] 
Maybe you’ll need some extra breaks, well, just take 
them then.’
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Several participants mentioned having made a con-
scious choice not to focus on their illness and all the 
associated negatives. One woman (52) stressed, “Yes, I 
changed my focus. Of course, sometimes I feel a bit down 
and then I just sit down at home and cry a few tears. And 
then I think “change your focus”. I prefer just to think I 
am not ill.’ An elderly woman (85) with a serious exhaus-
tion problem said, “When I feel a depression coming on 
and I’m very tired and I’ve got no energy, then I say, “You 
have no right to feel like this, you’ve just got no right”. 
And then it passes.’ Some participants pointed out that 
categorising themselves as healthy despite their cancer 
did not necessarily mean that they were repressing the 
disease; instead, it related to the role they wanted to play. 
One woman (51) who experienced severe side effects 
stressed that she did not want to consider herself to be ill: 
‘No, so I see myself as healthy. Because I don’t want to be 
ill.’ Several others pointed out that they managed to focus 
on the healthy and normal aspects of their life, which 
enabled them to live positively despite the cancer and the 
side effects of treatment.
Discussion
This study examined patients’ experiences living with 
GIST and undergoing TKI treatment, as well as how the 
experienced adverse effects significantly challenged their 
daily lives. The predominant patient narrative concerned 
living with treatment and how it was established as part 
of ‘a new normal’. More than half of the participants in 
the current study described how extensive, partially 
debilitating, self-reported side effects and complaints 
had a detrimental influence on their lives. Interestingly, 
none of the participants questioned their medical treat-
ment. The reason for this might be that the participants 
considered the life-prolonging effect of TKI treatment to 
outweigh the adverse effects. Our interpretation of a par-
adoxical self may relate to the fact that participants who 
were dependent on life-prolonging cancer treatment and 
who experienced adverse effects still considered them-
selves to be healthy. However, their experiences with 
imatinib or sunitinib, as treatments for metastatic GISTs, 
altered their self-identity and what good health meant to 
them. Many participants emphasised that being healthy 
and normal meant being able to still do what they could 
do before, for example, going to work or being busy with 
something that was enjoyable or important to them.
By conducting in-depth interviews with patients liv-
ing with metastatic GIST, we found that more than half 
of them told a story that did not comply with the pre-
vailing biomedical comprehension of the imatinib toxic-
ity profile. Their subjective experience with side effects 
of treatment had significant physical, practical and 
social consequences for their everyday life. Hence, we 
observed a gap between the biomedical perspective on 
disease that health professionals typically adopt and the 
individual lived experiences of patients with metastatic 
GIST. Understandably, the biomedical approach of health 
professionals and the pharmaceutical industry alike is 
more concerned with the objective medical side effects 
of a treatment than with its overall impact on patients’ 
daily lives. The biomedical model could be described as 
reductive and, thus, criticised for being too narrow. It is 
a model that primarily focuses on cure or extended sur-
vival but it says next to nothing about how disease affects 
the more practical, relational or existential aspects of life 
as experienced by the patients themselves, nor does it 
consider the psychosocial resources that patients need to 
cope with in their daily life. Research has shown that phy-
sicians tend to underestimate their patients’ health status 
[20] and to consider that side effects must be medical and 
life-threatening in order to be regarded as harmful. How-
ever, patients may blame ‘the pill’ for symptoms or chal-
lenges that are not necessarily related to their medication. 
For example, one patient reported being less happy as a 
side effect of imatinib. Whether this lack of happiness is 
a side effect, a consequence of the stressful situation of 
living with a chronic cancer or some other issue remains 
uncertain. As pointed out by Poort et al., fatigue is disa-
bling and not only associated with current TKI use, but 
also with psychological distress and physical functioning 
[12]. Nevertheless, we hypothesise that challenging and 
debilitating side effects, as experienced by patients with 
metastatic GIST, may not be noticed and given appropri-
ate attention. During follow up, it seems important that 
the oncologist develops a comprehensive picture of what 
it means for the patients to live with metastatic GIST. The 
subjective and psychosocial consequences of the treat-
ment should be captured, and communication on how to 
deal with this should be an essential part. However, it is 
not necessarily the oncologist who should be responsi-
ble for the supportive care. Cancer nurses, other health 
care professionals and peers might play important roles. 
Improved communication might help the patients to bet-
ter cope with the side effects that negatively impact their 
everyday life. Further research on how daily practical and 
psychosocial life is affected by the subjective side effects 
of cancer treatment, as well as how best help to patients 
to overcome those daily challenges, is hence warranted. 
Also, actively exploring dose reduction of imatinib tai-
lored to the patients’ side effect and disease control, as 
well as interventions like cognitive behavioural therapies, 
might be justified.
The majority of our participants described ‘a new nor-
mal’ involving new preconditions whereby they experi-
enced challenges, such as tiredness and fatigue, as well 
as a reduction in work capacity and social life, when 
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compared to their ‘old normal’. From a psychosocial 
perspective, serious disease can be understood as a bio-
graphical disruption and a serious incident in a person’s 
life. Their previous life story is disrupted, as is their iden-
tity [14, 21]. Our participants described how illness had 
broken into their daily life and altered their life experi-
ences. This experience of ‘otherness’ can lead to a sense 
of standing out negatively from the perceived norm, as 
well as to a reduced social life [21]. Most of our partic-
ipants were very keen to lead a life as normal as possi-
ble. Attempting to continue with the activities and social 
relationships that correspond to their pre-disease life is a 
feature of the biographical disruption seen in chronically 
ill people. However, their sense of normality had to be 
changed and adapted to the new constraints in their life. 
This appeared particularly evident when the participants 
expressed the wish to return to the roles they had before 
the disease struck [21]. Existing in a world of disease can 
be a challenging situation. Striving for normality in the 
form of a new normal can, for chronic GIST patients, 
represent a means of coping with physical and existential 
challenges and distancing oneself from the disease. It is 
hence vitally important that sufficient attention is being 
paid to this issue during the follow-up of such patients.
The fact that several of our participants emphasised 
that they considered themselves to be healthy, despite 
having metastatic cancer and experiencing side effects of 
the associated treatment, could be related to questions 
such as ‘what is health and when is a person healthy?’ An 
individual’s ability to cope and to achieve vital goals is 
more important than whether that individual is defined 
as healthy or ill. In fact, the articular-holistic health con-
cept stresses that health must be linked to action and 
function [22]. This view contradicts the prevailing notion 
of health as the absence of disease. In addition to being 
able to achieve vital goals and maintain everyday activ-
ity, health involves one’s ability to accomplish education 
and to work, to lead an active and social life, to have the 
opportunity to form close relationships and to establish 
a family, that is, living a normal life. In line with the find-
ings of this study, this may be of particular relevance to 
those living with metastatic GISTs and, therefore, fight-
ing everyday challenges.
Health is a way of being in the world. It is concerned 
with being in a meaningful relationship with others [23]. 
It has been emphasised that one cannot divide health into 
only somatic and psychological issues, since health is part 
of a being’s completeness (the whole of being), where we 
find our own well-being in the world in which we live. 
The prevailing paradigm in modern medicine has a uni-
lateral focus on science and technology that may coun-
teract the possibility to see the whole person, including 
that person’s health challenges and opportunities [23]. 
For chronic GIST patients, this means that cancer treat-
ment is a prerequisite for extended survival, although it 
may not be sufficient.
This study did have certain limitations. As with most 
qualitative studies, the small sample size limits its gener-
alisability. Nevertheless, the obtained narratives are rich 
and full of nuanced examples. In qualitative research, one 
does not seek representative data, but rather aims to illu-
minate the phenomena that participants experience from 
their own perspectives.
Conclusions
Advances in cancer research that result in new treat-
ments will, over the next few decades, probably result in 
more patients with different cancer diagnoses living in a 
chronic phase, which means that they cannot be cured, 
although they will remain in stable remission for several 
years. This should prompt more attention and research 
concerning how daily practical and psychosocial life is 
affected in patients with metastatic cancer who are in 
long-term remission. In this regard, metastatic GIST 
could serve as a model disease due to the high response 
rate and relatively long expected survival in these 
patients. Our findings indicate that, for those patients 
who are living in limbo between having metastatic can-
cer and receiving effective treatment, a holistic view of 
health on the part of healthcare providers is crucial. One 
vital goal should be to improve communication between 
healthcare professionals and cancer patients in order to 
secure a comprehensive follow-up with guidance on how 
to cope with, and adapt to, their new normal.
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